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ABSTRACT 
Tamakasvasa (asthma) is a mucous hypersecretory respiratory disease. The inspissated mucus produced by 
vitiated Kapha obstructs the bronchi and other small air passages in the pathological development of the 
disease. Physiologically Kapha dosa provides strength (Bala) to the body due to the intrinsic qualities 
unctuousness (Snigda), coldness (Sita), heaviness (Guru), slowness (Manda), smoothness (Slasna), softness 
(Mrisna), stability (Sthira) etc. Being an organ in the specific site of Kapha dosha i.e., thorax (Uras), 
production of mucus in lungs is normal. Etiological factors that irritate respiratory tract stimulate 
inflammatory process and due to this, mucus is produced in excess. Due to the excessive vitiation of qualities 
of Kapha the mucus turns highly viscous and the normal clearance of mucus by airflow and ciliary function is 
hampered. Thus gelatinous mucus plugs tend to develop in the airways. The gel-forming MUC genes MUC2, 
MUC5AC and MUC5B commonly seen in respiratory secretions and stomach, duodenum, gall bladder etc 
have major role in the formation of airway mucus. Due to the ingestion of unwholesome food stomach 
(Amasaya) where Kapha reside, act as the organ of origin of the disease. The main pharmacotherapeutic 
objective in the management of Tamakasvasa is reduction of airway obstruction and airflow limitation by 
enhancing mucus clearance. This can be achieved by altering the rheological properties of bronchial mucus 
and inhibition of mucus hyper secretion and airway hyper responsiveness by procedure based therapies and 
pharmacological methods of Sleshmavilayana, Srotomardavakarana and rationale use of taste specific drug 
therapy (Rasapravicarana chikitsa). 
KEYWORDS: Airway mucus hyper secretion, Tamaka svasa, Asthma, Rasapravicarana chikitsa. 
INTRODUCTION
Airway diseases appear a major group of lung 
disease that affect hundreds of millions of people all over 
the world. The main risk factors include tobacco smoking, 
indoor and outdoor air pollution, occupational chemicals 
and dusts, allergens and vulnerability. All types of airway 
diseases (Svasarogas) are caused by the simultaneous 
aggravation of Vata and Kapha doshas.[1] Respiratory 
system (Pranavaha srothas) is involved in the 
manifestation of these group of diseases and hence 
Svasaroga is considered as a dreadful disease.[2,3] Apart 
from the other four Svasarogas - Kshudra, Chinna, Maha 
and Urdha, Tamaka svasa (asthma) is caused 
predominantly due to the abundance of Kapha dosha.[4,5] 
Asthma is an exaggerated bronchoconstrictor response to 
stimuli that have little or no effect in normal subjects. The 
tracheobronchial tree shows increased responsiveness to 
both immunological and non-immunological stimuli. In 
pathological development of asthma, lesion is seen in the 
bronchi and other small air passages due to obstruction 
with inspissated mucus. Bronchial obstruction leads to 
bronchial muscle spasm, mucosal oedema and thick 
secretions. Asthma is clinically characterized by 
paroxysms of dyspnea, expiratory wheeze and productive 
cough. The disease is episodic in nature, with 
exacerbations and remissions.  
PHYSIOLOGY OF KAPHA DOSHA 
Doshas –Vata, Pitta and Kapha are the bio 
regulatory principles in the body and it is with these 
Doshas body (Sareera) survive. When they are balanced 
(Samya) with their normal functions, it is conducive to the 
preservation of health (Arogata). Disease (Roga) is nothing 
but the derangement (Vaisamyam) of their regular 
functions. [6] The non vitiated Doshas perform the functions 
situating in the lower, middle and upper part and preserve 
the body.[7] Wholesome (Hita) food (Ahara) and customary 
practices (Vihara) are the factors that maintain the 
balancing of Doshas. 
The specific site of Kapha dosha in the body is 
thorax (Uras). Other sites include throat (Kantha), head 
(Sira), lung (Kloma), joints (Parva), stomach (Amasaya), 
plasma (Rasadhatu), adipose tissue (Medodhatu), nostrils 
(Krana) and tongue (Jihva).[8] The important organ where 
Kapha reside is stomach (Amasaya). Stomach is that organ 
in the alimentary tract which receives all types of food 
materials for digestive process. Due to the fluid nature 
(Udaka guna) of Kapha in stomach, the food substances 
become moistened (Praklinna), split apart (Bhinna 
sankhata) and digest well (Sukhajara). Subsequently 
sweet, slimy and moisten food, produces sweet and cold 
Kapha in the stomach. Situating in the stomach, Kapha 
nourishes other sites of Kapha dosha by its own potency 
(Svasakti) and fluidity (Udaka karma).[9]  
By quality Kapha dosha is unctuous (Snigda), cold 
(Sita), heavy (Guru), slow (Manda), smooth (Slasna), soft 
(Mrisna) and stable (Sthira) in nature.[10] It is also white 
(Sveta) in colour, slimy (Pichila), and sweet (Madhura) 
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taste in non inflamed (Avidagtha) stage and saline 
(Lavana) in inflamed (Vidagda) stage.[11] Like other Doshas, 
Kapha also spreads all over the body to execute its normal 
functions. Due to the act of fluidity Kapha binds the joints 
(Sandhi samslesanam), provide unctuousness (Snehanam), 
heals (Ropanam) the injury, fills (Pooranam) the organs, 
and strengthens (Balam) and stabilizes (Sthairyam) the 
body.[12]  
PATHOPHYSIOLOGY OF VITIATED KAPHA DOSA 
Various factors are responsible for the vitiation of 
Doshas. This includes endogenous (Nija) and exogenous 
(Agantuja) causes.[13] Vitiation due to food and habits are 
endogenous causes because they have direct association 
with the Doshas in the body to manifest disease. 
Exogenous factors comprise various environmental factors 
like seasonal variation, pollution, etc and they have specific 
mechanism in the manifestation of disease. In order to 
produce disease the exogenous factors also have to link 
with the Doshas. Irrespective of the causes, whether they 
are directly associated or not, disease manifest only with 
the vitiation of bio regulatory principles or Doshas.[14] 
According to the diversity of causes Doshas vitiate in 
different ways and get lodged in specific sites or organs in 
the body.[15] Thus different types of diseases manifest by 
vitiating the body elements (Dhatus), their channels 
(Srothas), and excreta (Mala) and excretory routes 
(Malayanas).[16] 
The intrinsic property of Kapha is to provide 
strength (Bala) to the body. When it becomes abnormal, 
Kapha turns to be a waste product (Mala) and leads to 
diseased conditions.[17] The abnormal Kapha produces 
signs and symptoms like coldness (Saityam), itching 
(Kantu), stability (Sthairyam), thickness (Ulsedam), 
heaviness (Gouravam), unctuousness (Sneham), numbness 
(Supti), moistness (Kledam), swelling (Updeham), 
obstruction (Bandham), sweetness (Maduryam) and 
chronic occurrence (Chirakaritvam) of disease.[18] 
Inflammation (Upachaya), hindrance (Vistambha) and 
whitish (Souklyam) colour may also see due to vitiated 
Kapha.[19] Lethargy (Avasadam) and laziness (Tandra) are 
also associated with the increase in Kapha.[20] 
Manifestations include anemia (Svaityam), dislodgment of 
joints (Sladhangatvam), dyspnoea (Svasam), cough 
(Kasam) and deep sleep (Atinidra).[21] Anointing 
(Upalepam), immobility (Sthaimityam), oedema (Sopham), 
indigestion (Apakti) and salinity (Lavanarasa) are the 
other important Lakshanas in Kapha diseases. [22] 
RESPIRATORY MUCUS SECRETION  
The production of mucus in airways by Kapha 
dosha in the lungs is normal. Mucus is secreted from the 
mucosal epithelium and the connective tissue layer under 
the epithelium in the lung tissue. In the surface epithelium 
mucus is produced by the cells called goblet cells. In the 
connective tissue mucus is produced by sub mucosal 
glands. Airway mucus is a heterogeneous adhesive, 
viscoelastic gel composed of water, secreted polypeptides, 
lipids, glycoproteins (or mucins) and carbohydrates. It 
contains exogenous bacterial products, endogenous 
antibacterial secretions, cell-derived mediators and 
proteins, plasma-derived mediators and proteins and cell 
debris such as deoxyribonucleic acid (DNA).[23] 
Respiratory mucus present as a bilayer of an upper 
mucous sheet ("gel-phase") and a lower, more watery 
periciliary layer with low viscosity ("sol-phase"). A thin 
layer of surfactant lies between the sol and gel phases. 
Much of the mucus portion is produced by sub mucous 
glands and periciliary fluid by epithelial cells. The function 
of periciliary layer is “lubrication” of the beating cilia. 
Surfactant helps the easy spread of mucus over the 
epithelial surface. 
Respiratory tract secretion is an inherent part of 
the defense system that protects the airways against 
invading pathogens and environmental toxins.[24] 
Mucociliary clearance of trapped dust particles and foreign 
matter in the respiratory tract is the important function of 
mucus. The particles trapped in the sticky mucus layer are 
moved by the tips of beating cilia and are removed from 
the airways through the throat; where it is swallowed for 
gastrointestinal degradation. Mucus also contains 
antibacterial substance immunoglobulins - lactoferrin, 
which chelates iron necessary for the growth of some 
bacteria, and an antibacterial enzyme lysozyme. The high 
water content act as a humidifier of inspired air and 
prevent excessive fluid loss from the airway surface.[23,25] 
AIRWAY MUCUS HYPER SECRETION IN TAMAKASVASA 
(ASTHMA) 
When respiratory tract is exposed to irritants, 
Vata dosa aggravates and leads to increase of Kapha in the 
lungs. Simultaneously the situation stimulates 
inflammatory process and due to the activation of 
inflammatory response, mucus is produced in excess. 
Inflammation of the mucosa is responsible for mucus 
hyper production than any other causes in diseases of 
respiratory system26. The increased mucus due to 
inflammation may trigger cough reflex and is cleared as 
sputum from the respiratory tract. So Kapha vitiation in 
the lungs leads to an important sign – expectoration and 
spitting of sputum (Sleshmaudgiranam), in this disease27,28. 
Generally sputum contains expectorated mucus mixed 
with inflammatory cells, cellular debris, DNA and 
microorganisms. 
High viscosity is the peculiar character of mucus 
in asthma. The important qualities of Kapha such as 
unctuousness (Snigda), sliminess (Pichila), heaviness 
(guru), slowness (Manda), and stability (Sthira) contribute 
to the high viscous character of mucus. Due to the high 
viscous nature the mucus resist to flow and get obstructed 
in the airways. Normal clearance of mucus by airflow and 
ciliary function may also be hampered by high viscosity. 
Subsequently airways tend to develop gelatinous mucus 
plugs.[29] Mucus plug formation is due to stabilization of 
noncovalent interactions between extremely large mucins 
assembled from conventional-size subunits.[30] This 
suggests that the abnormal secondary structure due to 
defect in assembly of the mucin molecules leads to 
increase in viscosity of the mucus plugs. Increased airway 
plasma proteins (such as serum albumin) exudation also 
contributes to the plug formation. Structural modifications 
such as goblet cell hyperplasia (GCH) and hypertrophy of 
submucosal glands associated with increased mucin 
production is also seen in asthma. 
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It is explained that mucins produced in goblet 
cells and sub mucous glands have major role in the 
formation of airway mucus. Out of twenty human MUC 
genes so far identified, only nine, namely, MUC1, MUC2, 
MUC4, MUC5AC, MUC5B, MUC7, MUC8, MUC11, and 
MUC13, are expressed in the human respiratory tract.[31] 
Of these, MUC2, MUC5AC and MUC5B are the gel-forming 
mucins found in respiratory secretions. Among these the 
principal gel-forming mucins identified in both normal and 
pathological secretions are MUC5AC and MUC5B 
glycoproteins. In addition to lungs these MUC genes are 
distributed in stomach, duodenum, gall bladder, 
conjunctiva, middle ear, sublingual gland, laryngeal sub 
mucosal glands, esophageal glands and nasopharynx.[23] As 
described earlier most of these body parts are the sites of 
Kapha dosha and stomach (Amasaya), the important organ 
where Kapha reside has a major role in the manifestation 
of the disease.[32] 
The process of airway hyper secretion involves 
the distinct changes in phenotype of mucus-producing 
tissues and over expression of protein products of MUC 
genes. Two important characters are seen associated with 
the mucus hypersecretory phenotype in asthma. They are 
elevated mucin production that increases the quantity of 
intracellular mucin in airway secretary cells and elevated 
mucin exocytosis that increases the thickness and viscosity 
of the mucus gel.[33] The expression of MUC genes is 
regulated by inflammatory mediators and associated 
neurohormonal factors. In asthma, inflammation is 
mediated by allergen-specific helper T-cell type 2 (Th2) 
cytokines, including interleukin (IL) IL-9 and IL-13. IL-9 
may act predominantly via calcium-activated chloride 
channels (CLCA) and IL-13 through the activation of signal 
transducer and activator of transcription 6 (STAT6) and 
FOXA2 channels. Other inflammatory mediators include 
IL-1 beta, tumor necrosis factor-alpha (TNF-alpha) and 
cyclooxygenase (COX)-2. TNF-alpha act via NF-kappa B, 
and IL-1 beta via COX-2 channels. Epidermal growth factor 
receptor (EGF-R) signaling and FOXA2 also emerge as 
intracellular pathways for asthma.[34] These mediators not 
only induce mucin secretion but also up-regulate MUC 
gene expression with resultant increase in mucin synthesis 
and associated goblet cell hyperplasia. 
PHARMACOTHERAPEUTIC APPROACH IN MUCOUS 
HYPER SECRETION  
Increased volume of mucus is an important 
feature in Tamakasvasa, especially during the attacks. 
Usually the pathology of mucus hyper secretion is 
undervalued in the management of Tamakasvasa. Food 
substances ingested now a days with sweet taste (Madhura 
rasa), and unctuous (Snigdha), heavy (Guru), slimy 
(Picchila) and cold (Sita) qualities are the major cause of 
Kapha vitiation that leads to increased mucus sputum. The 
accumulation of mucus in the airway tree contributes to 
chronic airway inflammation, airway obstruction, airway 
hyper responsiveness and asthma exacerbation. The 
relationship with airway obstruction and physical 
properties of the sputum has been demonstrated in many 
studies.[35] There will be a greater decrease in the 
ventilator capacity when the sputum is thick. The 
morbidity and mortality of the disease is associated with 
the mucus plugs in the airways.[36] 
There are two objectives in the management of 
mucus hypersecretion in tamkasvasa, namely short-term 
relief of symptoms and long-term benefit. It is primarily 
the vitiated kapha as phlegm gets lodged in the airways 
(srotas) that put the patient in serious sufferings. Hence, 
reduction of airway obstruction and airflow limitation by 
enhancing mucus clearance is the primary objective for 
short-term relief of symptoms. This involves altering the 
rheological properties of bronchial mucus and thereby 
promotes expectoration. Adhesivity and cohesivity 
(“stickiness” and “stringiness”) produced by tenacity is the 
major cause of adhesion of the mucus to the epithelium in 
airways. Mucociliary clearance can be increased by 
decreasing the tenacity and changing the viscoelasticity of 
mucus. Next step entails inhibition of mucus hyper 
secretion and airway hyper responsiveness to reduce the 
amount of luminal mucus in the airways. The long-term 
benefit embraces pharmacotherapeutic approach for 
reversal of the hypersecretory phenotype and reducing the 
number of goblet cells and the size of the sub mucosal 
glands.[37] 
Management of mucus hyper secretion can be 
done by procedure based therapies and pharmacological 
methods. Liquefaction (Sleshmavilayana) is the therapeutic 
procedure suitable for the clearance of thick phlegm 
lodged in the Srotas. Along with the liquefaction, softening 
of channels (Srotomardavakarana) is also needed to 
facilitate the free movement of liquefied phlegm. In order 
to avoid hindrance to mucociliary clearance employ 
measures to pacify the vitiated Vata dosha as well.[38] 
Person who is afflicted with copious sputum and has 
sufficient strength (Sareerabala) purification (Sodhana) 
therapies Vamana along with Virechana or Vamana and 
Virechana are necessary. If the patient is weak, treatment 
at the outset with unctuous fomentation therapy after 
applying suitable oil mixed with salt on chest, flanks and 
back is beneficial. These methods are significantly effective 
both in removing phlegm from small distal bronchioles to 
large central bronchi and in promoting their final removal 
from the lungs. 
Pharmacological methods check the production of 
phlegm in the airways due to vitiation of Kapha dosa. 
Administration of drugs having taste (rasa) with acrid 
(Katu), Tikta (bitter) and astringent (Kashaya) 
consecutively, according to taste specific therapy 
(Rasapravicarana chikitsa) pacify the diseases caused by 
vitiated Kapha. The properties (Guna) of these Rasas help 
to modify the properties of bronchial mucus and reduce or 
inhibit mucus hyper secretion and airway hyper 
responsiveness. Katu rasa acts on the viscid and thick 
Kapha and desiccates hyper secretions due to ununctous 
(Rooksha), skinny (Laghu) hot (Ushna) and cleansing 
(Vaisadya) properties. The Tikta rasa administered 
thereafter, reduces the sweetness produced in mouth and 
dries up the increased Kapha as a whole due to ununctous 
(Rooksha) and skinny (Laghu) properties. Subsequent use 
of Kashaya rasa, inhibits the over production of Kapha and 
reduces the unctuous nature due to the action of 
ununctous (Rooksha) property.[39] The rationale use of 
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food considering the taste approach (Rasapravicarana) 
helpful in maintaining the normalcy of Dosas, especially 
Kapha dosa and the fine customary practices accomplish 
long-term benefits in Tamkasvasa. 
CONCLUSION  
Mucus hypersecretion due to Kapha aggravation 
play an important role in the manifestation of 
Tamakasvasa. The effective management of increased 
mucus in Tamakasvasa is possible only by the clearance of 
phlegm from the air passages and inhibition of over 
production of mucus in the lungs. This can be achieved by 
the administration of procedure based cleansing therapies, 
taste specific drug therapy; use of wholesome food (Ahara) 
and by adopting healthy practices (Vihara) 
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